2023³â ´ëÇÑ°©»ó¼±ÇÐȸ Ãß°èÇмú´ëȸ°¡ 8¿ù 25ÀÏ(±Ý), 26ÀÏ(Åä) ¾çÀÏ°£
¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÄÁº¥¼Ç¼¾ÅÍ¿¡¼ °³ÃֵǾú´Ù.
- °©»ó¼±¾Ï Áø·á ±Ç°í¾È °³Á¤¾È °ü·Ã °øûȸ
º» Çмú´ëȸ ±â°£ Áß ´ëÇÑ°©»ó¼±ÇÐȸ »êÇÏ Áø·áÁöħÁ¦Á¤À§¿øȸ¿¡¼´Â °øÇ¥¸¦
¾ÕµÎ°í ÀÖ´Â ´ëÇÑ°©»ó¼±ÇÐȸ °©»ó¼±¾Ï Áø·á±Ç°í¾È °³Á¤¾ÈÀÇ ¼¼ºÎÀûÀÎ ³»¿ë°ú
°ø½ÄÀûÀÎ ±¹¹® ¿ë¾î ¼±Á¤¿¡ °üÇÏ¿© °¢ ºÐ¾ßº° ÆгΠÅä·Ð ¹× ÇöÀå ÁúÀÇ ÀÀ´äÀ»
ÅëÇÏ¿© ´Ù¾çÇÑ ÀÇ°ßÀ» ¼ö·ÅÇÏ´Â °øûȸ¸¦ °³ÃÖÇÏ¿´´Ù.
- °©»ó¼±Áúȯ ÷´Ü Ä¡·á¹ý¿¡ °üÇÑ ÄÁ¼¾¼½º Åä·Ð
º» Çмú´ëȸ¿¡¼´Â ¼Ò¾Æ°©»ó¼±¾Ï¿¡ ´ëÇÑ ¼ö¼ú ¹× Ç¥ÀûÄ¡·áÁ¦, ºÎ°©»ó¼±Áúȯ,
°©»ó¼±¼öÁú¾Ï µî »ó´ëÀûÀ¸·Î µå¹°Áö¸¸ Áö¼ÓÀûÀ¸·Î ¹ßÀüÇÏ°í ÀÖ´Â ºÐ¾ß¿¡ ´ëÇÏ¿©
³»°ú, ¿Ü°ú, º´¸®, ¿µ»óÀÇÇÐ µî ÃֽŠÁö°ß¿¡ ´ëÇÑ ¹ßÇ¥¿Í Åä·ÐÀÌ ÀÌ·ç¾îÁ³´Ù.
¶ÇÇÑ °©»ó¼±Á¾¾ç¿¡ ´ëÇÑ °íÁÖÆÄÀýÁ¦¼úÀ» ºñ·ÔÇÑ ºñ¼ö¼úÀû Ä¡·á¿¡ ´ëÇÑ ÃÖ½Å
±â¼úÀ» È°¿ëÇÑ Áõ·Ê ¹× ¿¬±¸ °á°ú°¡ ¹ßÇ¥µÇ¾ú°í, °ü·Ã Àü¹®°¡µéÀÇ Åä·ÐÀÌ
À̾îÁ³´Ù.
- ±¹³»¿Ü ¼®ÇеéÀÇ °¿¬
À̹ø Çмú´ëȸ¿¡¼´Â Æ÷½ºÆ® Äڷγª ½Ã±â¸¦ ¸ÂÀÌÇÏ¿© ±¹³»¿Ü ¼®ÇеéÀÇ ÇöÀå
°¿¬ÀÌ Å« Àα⸦ ²ø¾ú´Ù. ±³ÅäºÎ¸³ÀÇ°ú´ëÇÐÀÇ ½Ã°Ô·ç È÷¶ó³ë ±³¼ö°¡
±¹¼ÒÁøÇ༺ °©»ó¼±¾ÏÀÇ Ä¡·á¿¡ ´ëÇØ °¿¬ÇÏ¿´°í, Á¸½ºÈ©Å²½º ÀÇ°ú´ëÇÐÀÇ »çÀ̵å
¾Ë¸® (Syed Z. Ali) ±³¼ö°¡ ÃÖ±Ù °³Á¤µÈ °©»ó¼± ¼¼Æ÷°Ë»çÀÇ Ç¥ÁØ Áø´Ü ±âÁØÀÎ
º£µ¥½º´Ù (Bethesda) ½Ã½ºÅÛ¿¡ ´ëÇÏ¿© °¿¬ÇÏ¿´´Ù. °©»ó¼±¾ÏÀÇ Áø´Ü°ú Ä¡·á¿¡
´ëÇÑ ÃֽŠÁ¤º¸¸¦ ±³·ùÇÏ°í, °¢ ºÐ¾ß ±¹³» ÀÓ»ó Àü¹®°¡µé°úÀÇ ¿¶í Åä·ÐÀÌ
À̾îÁ³´Ù. ¶ÇÇÑ, °©»ó¼±ÇÐȸ ȸÀåÀÎ ¼¿ïÀÇ´ë ¹ÚµµÁØ ±³¼ö°¡ ȸÀå °¿¬À»
ÅëÇÏ¿© ±¹³» °©»ó¼±ÇÐ ¿¬±¸·Â ¹ßÀüÀ» À§ÇÑ ºñÀüÀ» Á¦½ÃÇÏ¿© Å« È£ÀÀÀ» ¹Þ¾Ò´Ù.
- ¿¬±¸À§¿øȸ Çмú»ó °á°ú ¹ßÇ¥
¿¬±¸À§¿øȸ Çмú»óÀ» ¼ö»óÇÑ ÇÐȸ ȸ¿ø ¿¬±¸ÀÚµéÀÇ ¿¬±¸ °á°ú ¹ßÇ¥µµ ¸¹Àº
°ü½ÉÀ» ¹Þ¾Ò´Ù. °©»ó¼±¾ÏÀÇ Ã·´Ü Áø´Ü ±â¼úÀÎ ¾×ü »ý°Ë (liquid biopsy)¿¡
´ëÇÑ ¿¬±¸¸¦ ºñ·ÔÇÏ¿© ±¹³» °©»ó¼±¾Ï ºòµ¥ÀÌÅ͸¦ È°¿ëÇÑ Àå±â °Ç° °á°ú¿¡ ´ëÇÑ
´ë±Ô¸ð ¿¬±¸ °á°ú, ÃÖ±Ù °ü½ÉÀÌ Áõ°¡ÇÏ°í ÀÖ´Â °©»ó¼±¾Ï ¼ö¼ú ÈÄ È¯ÀÚµéÀÇ »îÀÇ
Áú (Quality of Life)°ú °ü·ÃµÈ ÀþÀº ¿¬±¸ÀÚµéÀÇ ¿¬±¸ °á°ú°¡ ¹ßÇ¥µÇ¾î Å«
°ü½ÉÀ» ¹Þ¾Ò´Ù.
- ½ÅÀÓ È¸Àå´Ü Ãß´ë
Á¦8´ë ÀÓ¿øÁøÀÇ ÀӱⰡ 8¿ù 31ÀϺηΠ¸¸·áµÊ¿¡ µû¶ó º» ÇÐȸ ±â°£ Áß °³ÃÖµÈ
´ëÇÑ°©»ó¼±ÇÐȸ ÃÑȸ¿¡¼´Â Â÷±â Á¦9´ë ȸÀå (°¸ª¾Æ»êº´¿ø ³ªµ¿±Ô ±³¼ö)°ú ÀÌ»çÀå
(¼º±Õ°üÀÇ´ë ±è¼±¿í ±³¼ö)ÀÌ Ãß´ë ¹× ÀÎÁصǾú´Ù.
<´ëÇÑ°©»ó¼±ÇÐȸ 2023 Ãß°èÇмú´ëȸ ¼ö»ó ³»¿ª>
±¸ºÐ | ¿¬±¸ Á¦¸ñ | ¼º¸í | ¼Ò¼Ó |
---|---|---|---|
¿ì¼ö ¿¬±¸ÀÚ»ó | Establishment of parathyroid cancer registry and a multicenter retrospective study on the clinicopathological characteristics and outcomes of parathyroid cancer | Á¤Á¾ÁÖ | ¿¬¼¼ÀÇ´ë ¿Ü°ú |
ÀþÀº ¿¬±¸ÀÚ»ó | The starting dosage of levothyroxine for subclinical hypothyroidism during pregnancy | ¹ÚÇöÁÖ | Â÷ÀÇ°ú´ë ³»°ú |
±âÃÊÀÇÇבּ¸»ó | Differentiation between thyroid follicular adenoma and thyroid follicular cancer using circulating miRNA | À̺´ÁÖ | ºÎ»êÀÇ´ë À̺ñÀÎÈÄ°ú |
Establishment of an immune map based on single cell-based metabolic changes | ÀÌÀܵð | ¿¬¼¼ÀÇ´ë ¿Ü°ú | |
ÃÖ¿ì¼ö³í¹®»ó | ÃÖ¼Ò Ä§½ÀÀû °³¹æ °©»ó¼± ¿±ÀýÁ¦¼ú¿¡¼ ÇǺΠÀü±ØÀ» ÀÌ¿ëÇÑ ¹ÝȸÈĵνŰæÀÇ ¼ö¼ú Áß ½Å°æ°¨½Ã¼ú | õ¿ëÀÏ/À̺´ÁÖ | ºÎ»êÀÇ´ë À̺ñÀÎÈÄ°ú |
°©»ó¼±¾Ï ¼ö¼ú ȯÀÚÀÇ ±³À° ¿ä±¸µµÀÇ º¯È: 2012³â°ú 2020³â ºñ±³ | À̹ÎÁø/ÀÌ¿ë»ó | °³²¼¼ºê¶õ½ºº´¿ø/ ¿¬¼¼ÀÇ´ë ¿Ü°ú |
|
±¹Á¦ÇÐȸ³í¹®»ó | ASSOCIATION BETWEEN RADIOACTIVE IODINE TREATMENT AND CANCER RISK IN GRAVES" DISEASE: A NATIONWIDE COHORT STUDY | ±è°æÁø | °í·ÁÀÇ´ë ³»°ú |
Transcriptomic analysis reveals tumor microenvironment plays important role in nodal metastasis of papillary Microcarcinomas | ±è¹ÌÁø | ºÎ»êÀÇ´ë ³»°ú | |
TSH monitoring and levothyroxine prescribing after thyroid lobectomy: 1-year interim analysis of a Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER) study | ±èÀ¯Çü | ¼¿ïÀÇ´ë ³»°ú | |
Morphometric analysis of lateral cervical lymph node metastasis in papillary thyroid carcinoma using digital pathology | ±èä¾Æ | ¿ï»êÀÇ´ë ³»°ú | |
Can TERT promoter mutation be a poor prognostic factor in undifferentiated thyroid carcinoma? | À¯ÇöÁø | ¼º±Õ°üÀÇ´ë ³»°ú | |
Diagnostic performance of ultrasound-based risk stratification systems for thyroid nodules: a systematic review and meta-analysis | ÁÖ¸®È÷ | °í·ÁÀÇ´ë ¿µ»óÀÇÇаú | |
ÃÖ¿ì¼ö¿¬Á¦»ó | Initial Tumor Volume Doubling Time in Active Surveillance of Low-risk Papillary Thyroid Microcarcinoma | ±èä¾Æ | ¿ï»êÀÇ´ë ³»°ú |
Evaluation of residual lesions with immediate postoperative CT in recurrent thyroid cancer | ±èÇö¼º | ¼¿ïÀÇ´ë À̺ñÀÎÈÄ°ú | |
¿ì¼ö¿¬Á¦»ó | Revaluation of core needle biopsy for diagnosing follicular neoplasm | ±è¸í°æ | ¼º±Õ°üÀÇ´ë ¿µ»óÀÇÇаú |
Effects of Neoadjuvant Chemoradiotherapy on Anaplastic Thyroid Carcinoma: A Single-Center Experience | ÀÌÁø¼® | ¿¬¼¼ÀÇ´ë ¿Ü°ú | |
Extent of thyroidectomy for solitary papillary thyroid carcinoma confined in the isthmus | À̽ÂÈ£ | ¼¿ïÀÇ´ë ¿Ü°ú | |
Initial Clinical Outcomes of Papillary Thyroid Cancer with TERT Promoter Mutation from Real World Data | À¯ÁöÇö | ¼º±Õ°üÀÇ´ë ³»°ú | |
Risk Stratification of incidental 18F-Fluorodeoxyglucose-Avid Thyroid Nodules Based on Six Societies¡¯ Ultrasound Risk Stratification Systems | ½Å俵 | ¿ï»êÀÇ´ë ¿µ»óÀÇÇаú | |
Is RFA effective in treating thyroid nodules larger than 4 cm? | ±è¿¬Àç | °¡Å縯ÀÇ´ë ¿µ»óÀÇÇаú | |
¿ì¼öÆ÷½ºÅÍ»ó | In Vivo Imaging of Hybrid Extracellular Vesicle Mimetics Engineered from Natural Killer and Red Blood Cells as a Platform for Targeting Thyroid Tumor | Ramya Lakshmi Rajendran | °æºÏÀÇ´ë ÇÙÀÇÇаú |
Active surveillance in patients with low-risk papillary thyroid carcinoma as an acceptable management option with additional benefits: A comprehensive systematic review | ±èÈñ°æ | Àü³²ÀÇ´ë ³»°ú | |
Comparative study for preoperative localization of 4-dimensional CT, US, 99mTc-Sestamibi SPECT/CT in solitary primary hyperparathyroidism | ±ÇÇÏ´Ì | ºÎ»êÀÇ´ë À̺ñÀÎÈÄ°ú |